Clinical Development ▲ Sign in to save

• ▲ Robin Besuyen

  Stedelijk Museum Amsterdam Medicine
  1.56k

  citations

  16

  h-index

  37

  Aachen papers
• ▲ D. de Vries

  Wageningen University & Research Medicine
  124

  citations

  5

  h-index

  4

  Aachen papers
• ▲ Dick de Vries

  Medicine
  109

  citations

  5

  h-index

  7

  Aachen papers
• ▲ R. Besuyen

  Galapagos (Netherlands) Medicine
  2

  citations

  1

  h-index

  1

  Aachen papers

4 results

• Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial)

  2021 Lara D. Veeken article Medicine Spondyloarthritis Studies and Treatments Open access

  38

  citations
• Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial

  2021 Lara D. Veeken article Medicine Spondyloarthritis Studies and Treatments Open access

  26

  citations
• POS0092 HERPES ZOSTER IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM

  2021 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies

  10

  citations
• Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study

  2025 RMD Open article Medicine Rheumatoid Arthritis Research and Therapies Open access

  8

  citations
• OP0126 INFECTIONS AND SERIOUS INFECTIONS IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM

  2021 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access

  3

  citations
• POS0235 INTEGRATED SAFETY ANALYSIS UPDATE FOR FILGOTINIB (FIL) IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS (RA) RECEIVING TREATMENT OVER A MEDIAN OF 2.2 YEARS (Y)

  2022 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access

  2

  citations
• POS0829 SAFETY AND EFFICACY OF FILGOTINIB: AN UPDATE FROM THE DARWIN 3 PHASE 2 LONG-TERM EXTENSION WITH A MAXIMUM OF 8.2 YEARS OF EXPOSURE

  2023 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access

  2

  citations
• POS0051 AN UPDATE ON THE INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS OVER A MEDIAN OF 4.3 YEARS

  2024 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies

  1

  citations
• P133 Filgotinib in patients with RA with inadequate response to methotrexate: FINCH 1 52-week efficacy and patient reported outcomes data

  2021 Lara D. Veeken conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access

  0

  citations
• POS0657 GEOGRAPHIC VARIATION OF SAFETY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM

  2021 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies

  0

  citations
• POS0658 GEOGRAPHIC VARIATION OF EFFICACY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM

  2021 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access

  0

  citations
• P123 Safety and efficacy of filgotinib, an update from the DARWIN 3 phase 2 long-term extension with a maximum of 8.2 years of exposure

  2024 Lara D. Veeken article Medicine Rheumatoid Arthritis Research and Therapies Open access

  0

  citations
• AB0689 SUSTAINED PATIENT MEANINGFUL OUTCOMES OF PAIN AND FATIGUE RELIEF AND IMPROVED PHYSICAL FUNCTIONING WITH FILGOTINIB IN RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS

  2024 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies

  0

  citations
• P115 Long-term efficacy of filgotinib monotherapy and combination therapy: interim results from a post hoc analysis of the FINCH 4 study

  2025 Lara D. Veeken conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access

  0

  citations
• OA12 An update on the integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis over a median of 4.3 years

  2025 Lara D. Veeken conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access

  0

  citations

15 results